Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

93.49 +0.90 (+0.97%)
Streaming Delayed Price Updated: 12:18 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
STRATA Skin Sciences Soars as Landmark Study Reveals Superior Vitiligo Treatment Efficacy
STRATA Skin Sciences Inc. (NASDAQ: SSKN) witnessed a dramatic surge in its stock price today, climbing 51.18% following the publication of a groundbreaking peer-reviewed study. The research highlights... 
Via MarketMinute
Topics Intellectual Property
Jim Cramer Spotlights These Undervalued S&P 500 Stocks With Growth Potential Amid Skyrocketing Market
In a recent episode of "Mad Money," Jim Cramer identified several stocks in the S&P 500 that he believes are undervalued, offering growth potential despite the market's record highs. 
Via Benzinga
Topics Stocks
13 Analysts Have This To Say About Incyte
 
Via Benzinga
Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer
From Incyte
Via Business Wire
Incyte Stock: A Deep Dive Into Analyst Perspectives (11 Ratings)
 
Via Benzinga
FDA Expands Incyte's Opzelura Approval To Treat Atopic Dermatitis In Children
FDA approves Incyte's Opzelura cream for children aged two and older with atopic dermatitis, expanding its use beyond teens and adults. 
Via Benzinga
Incyte Corp (NASDAQ:INCY) Emerges as a Top Value Investing Candidate
Incyte Corp (INCY) presents a strong value investing case with low P/E ratios, robust financial health, and high profitability in the biotech sector. 
Via Chartmill
Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis
From Incyte
Via Business Wire
Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025
From Incyte
Via Business Wire
2 S&P 500 Stocks with Exciting Potential and 1 We Avoid
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some... 
Via StockStory
Topics Stocks
Uncover the latest developments among S&P500 stocks in today's session.
Curious about the top performers within the S&P500 index one hour before the close of the markets on Friday? Dive into the list of today's session's top gainers and losers for a comprehensive... 
Via Chartmill
3 Unpopular Stocks That Deserve a Second Chance
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can... 
Via StockStory
Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the European Association of Dermatology and Venerology 2025 Congress
From Incyte
Via Business Wire
Incyte Launches HS TRUTHS to Spotlight the True Lived Experience of Hidradenitis Suppurativa
From Incyte
Via Business Wire
Incyte (INCY) Stock Is Up, What You Need To Know
Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) jumped 2.4% in the afternoon session after Barclays initiated coverage on the stock with an Overweight rating, helping the shares... 
Via StockStory
Topics Economy
Tuesday's session: top gainers and losers in the S&P500 index
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Tuesday. 
Via Chartmill
1 Profitable Stock to Keep an Eye On and 2 We Question
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my... 
Via StockStory
Can Incyte Deliver on 447% EPS Forecasts and Pipeline Hype?
Analysts expect nearly 450% EPS growth in 2025, making execution on its core portfolio critical for sustaining the outperformance experienced so far YTD. 
Via MarketBeat
Incyte Corp (NASDAQ:INCY): A Prime Candidate for Value Investors Seeking Undervalued Stocks
Discover Incyte Corp (INCY), an undervalued biotech stock with strong profitability, solid financial health, and promising growth potential for value investors. 
Via Chartmill
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
S&P 500 Losers: 22 Stocks With Negative Returns Over Past 10 Years, And This One's Getting The Boot
The S&P 500 Index is up over 200% over the past decade, but 22 stocks have declined during that period, and one is set to be removed soon. 
Via Benzinga
Topics Stocks
Incyte Announces the Appointment of Soni Basi as Executive Vice President and Chief Human Resources Officer
From Incyte
Via Business Wire
1 Mid-Cap Stock with Solid Fundamentals and 2 We Find Risky
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract... 
Via StockStory
2 Mooning Stocks with Exciting Potential and 1 We Ignore
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial... 
Via StockStory
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
Immuno-Oncology Stocks Q2 In Review: Incyte (NASDAQ:INCY) Vs Peers
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the immuno-oncology industry, including Incyte (NASDAQ:INCY) and its peers. 
Via StockStory
Topics Artificial Intelligence
Sotera Health Company, Incyte, Exact Sciences, Bausch + Lomb, and Addus HomeCare Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer... 
Via StockStory
Topics Economy Lawsuit
INCY Q2 Deep Dive: Product Launches and Pipeline Progress Underpin Revenue Growth
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 16.5% year on year to $1.22 billion. Its non-GAAP profit of... 
Via StockStory
1 Momentum Stock for Long-Term Investors and 2 Facing Challenges
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to new product launches, positive news, or even a dedicated social media... 
Via StockStory
Beyond The Numbers: 12 Analysts Discuss Incyte Stock
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.